Neurocognitive Disorders
Conditions
Brief summary
The development of biological biomarkers reflecting neuropathology has enhanced the diagnostic precision of Alzheimer's disease over the past decade, compared to the clinical diagnosis that suffers from low specificity. Patients undergoing evaluation in specialized memory clinics suspected of major or minor neurocognitive disorder are notably examined through a lumbar puncture to measure beta-amyloid 42, beta-amyloid 40, total tau, and phosphorylated tau in the cerebrospinal fluid (CSF). The purpose of this clinico-biological collection is to better characterize the existing biomarkers used in clinical practice, as well as the development of new diagnostic or prognostic biomarkers for neurodegenerative diseases causing neurocognitive disorder (Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration, in particular). The primary objective is to gain a better understanding of conventional biomarkers and to develop new diagnostic and prognostic biomarkers for neurocognitive diseases: establishing a prospective clinico-biological collection of patients evaluated in clinical practice for a neurocognitive disorder.
Interventions
OTHERSampling
Blood and cerebrospinal fluid sampling during the diagnostic visit
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Adult patient * Not under legal guardianship * Clinical indication for blood and cerebrospinal fluid (CSF) biomarkers measurement during a day hospital stay for Alzheimer's disease (beta-amyloid peptide, tau protein). * Signature of the research consent form.
Exclusion criteria
* Not affiliated with a social security scheme. * Patient under State Medical Aid (AME).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of new biomarkers for neurodegenerative diseases | Up to 10 years |
Secondary
| Measure | Time frame |
|---|---|
| Description of the level of usual biomarkers by type of dementia | Up to 10 years |
| Evaluation of the relationship between biomarker levels and cognitive evolution measured in routine care | Up to 10 years |
| Comparison of biomarker levels in neurodegenerative pathologies and psychiatric pathologies with cognitive expression | Up to 10 years |
Contacts
Primary ContactClaire Paquet, Pr
Backup ContactJérôme Lambert, Pr
Outcome results
None listed